Determination of the 161Tb half-life

Collins, S.M.; Gilligan, Chris; Pierson, Bruce D.; Ramírez, Noelia; Goodwin, Matthew A.; Pearce, Andy; Archambault, B.; Haney, Morgan M.; Regan, P.H.

doi:10.1016/j.apradiso.2022.110140

Cited by 12 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Terbium-161 is a highly promising radionuclide for β - -therapy as it decays by β - -emission (E β-,av = 154 keV) to dysprosium-161 with a half-life of 6.96 days ( Table 1 ) 8 . Furthermore, the simultaneous emission of γ-rays at 48.9 keV (I γ =17.0%) and 74.6 keV (I γ = 10.3%) makes terbium-161 suitable for SPECT imaging 9 .…”

Section: Radionuclide Properties and Production Methods Of The Four C...mentioning

confidence: 99%

See 1 more Smart Citation

Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside

Van Laere,

Koole,

Deroose

et al. 2024

Theranostics

View full text Add to dashboard Cite

Terbium features four clinically interesting radionuclides for application in nuclear medicine: terbium-149, terbium-152, terbium-155, and terbium-161. Their identical chemical properties enable the synthesis of radiopharmaceuticals with the same pharmacokinetic character, while their distinctive decay characteristics make them valuable for both imaging and therapeutic applications. In particular, terbium-152 and terbium-155 are useful candidates for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging, respectively; whereas terbium-149 and terbium-161 find application in α- and β - -/Auger electron therapy, respectively. This unique characteristic makes the terbium family ideal for the “matched-pair” principle of theranostics. In this review, the advantages and challenges of terbium-based radiopharmaceuticals are discussed, covering the entire chain from radionuclide production to bedside administration. It elaborates on the fundamental properties of terbium, the production routes of the four interesting radionuclides and gives an overview of the available bifunctional chelators. Finally, we discuss the preclinical and clinical studies as well as the prospects of this promising development in nuclear medicine.

show abstract

Section: Radionuclide Properties and Production Methods Of The Four C...mentioning

confidence: 99%

“…Decay characteristics and applications of clinically interesting terbium radionuclides. (IC = internal conversion)[7,8,9].…”

mentioning

confidence: 99%

Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside

Van Laere,

Koole,

Deroose

et al. 2024

Theranostics

View full text Add to dashboard Cite

show abstract

“…Digital twins for maintenance [43] require the various faults that can occur within a machine to be identified and implemented within a model that can use measured data to estimate either the likelihood of a failure occurring within a given period or the expected time to the next failure. These estimations are likely to have similar statistical qualities to radioactive decay events, and may be able to benefit from data analysis techniques used to calculate half-lives [44]. In addition, advanced techniques for early warning signals such as tipping point analysis [45] have been developed by NMIs that could be implemented as digital twins to identify signs that the state of the machine has changed and so some form of maintenance may be required.…”

Section: Metrology For Digital Twins?mentioning

confidence: 99%

Digital twins for metrology; metrology for digital twins

Wright,

Davidson

2024

Meas. Sci. Technol.

View full text Add to dashboard Cite

Digital twinning is a rapidly growing area of research. Digital twins combine models and data to provide up-to-date information about the state of a system. They support reliable decision-making in fields such as structural monitoring and advanced manufacturing. The use of metrology data to update models in this way offers benefits in many areas, including metrology itself. The recent activities in digitalisation of metrology offer a great opportunity to make metrology data “twin-friendly” and to incorporate digital twins into metrological processes. This paper discusses key features of digital twins that will inform their use in metrology and measurement, highlights the links between digital twins and virtual metrology, outlines what use metrology can make of digital twins and how metrology and measured data can support the use of digital twins, and suggests potential future developments that will maximise the benefits achieved.

show abstract

“…More recently, the radiolanthanide [ 161 Tb]Tb has been introduced for therapeutic applications because it emits β − particles (E β av = 154 keV) as well as γ-radiation (E γ = 49 keV, I = 17.0%; E γ = 75 keV, I = 10.0%) that are suitable for therapeutic purposes and single-photon emission computed tomography (SPECT), respectively ( Müller, Umbricht, et al, 2019 ). [ 161 Tb]Tb decays to the stable 161 Dy with a half-life of 6.89 days ( Collins et al, 2022 ). Also, [ 161 Tb]Tb is very similar to [ 177 Lu]Lu in terms of radiochemical properties, although the γ-radiation emitted by [ 161 Tb]Tb is of a lower energy.…”

Section: Introductionmentioning

confidence: 99%

The Radiolabeling of [161Tb]-PSMA-617 by a Novel Radiolabeling Method and Preclinical Evaluation by In Vitro/In Vivo Methods.

UYGUR,

Sezgin,

Parlak

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Prostate cancer (PC) is the most common type of cancer in elderly men, with a positive correlation with age. As resistance to treatment has developed, particularly in the progressive stage of the disease and in the presence of microfocal multiple bone metastases, new generation radionuclide therapies have emerged. Recently, [161Tb], a radiolanthanide introduced for treating micrometastatic foci, has shown great promise for treating prostate cancer. Results In this study, Terbium-161 [161Tb]Tb was radiolabeled with prostate-specific membrane antigen (PSMA)-617 ([161Tb]-PSMA-617) and the therapeutic efficacy of the radiolabeled compound investigated in vitro and in vivo. [161Tb]-PSMA-617 was found to have a radiochemical yield of 97.99 ± 2.01% and was hydrophilic. [161Tb]-PSMA-617 was also shown to have good stability, with a radiochemical yield of over 95% up to 72 hours. In vitro, [161Tb]-PSMA-617 showed a cytotoxic effect on LNCaP cells but not on PC-3 cells. In vivo, scintigraphy imaging visualized the accumulation of [161Tb]-PSMA-617 in the prostate, kidneys, and bladder. Conclusions The results suggest that [161Tb]-PSMA-617 can be an effective radiolabeled agent for the treatment of PSMA positive foci in prostate cancer.

show abstract

Determination of the 161Tb half-life

Cited by 12 publications

References 34 publications

Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside

Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside

Digital twins for metrology; metrology for digital twins

The Radiolabeling of [161Tb]-PSMA-617 by a Novel Radiolabeling Method and Preclinical Evaluation by In Vitro/In Vivo Methods.

Contact Info

Product

Resources

About